4//SEC Filing
Petrucci Gary M 4
Accession 0000914190-09-000239
CIK 0001222929other
Filed
Feb 26, 7:00 PM ET
Accepted
Feb 27, 7:10 PM ET
Size
36.0 KB
Accession
0000914190-09-000239
Insider Transaction Report
Form 4
Petrucci Gary M
Director
Transactions
- Disposition to Issuer
Stock Option (right to buy)
2009-02-25−30,000→ 0 total→ Common Stock (30,000 underlying) - Disposition to Issuer
Stock Option (right to buy)
2009-02-25−6,680→ 0 total→ Common Stock (6,680 underlying) - Disposition to Issuer
Stock Option (right to buy)
2009-02-25−38,320→ 0 total→ Common Stock (38,320 underlying) - Disposition to Issuer
Stock Option (right to buy)
2009-02-25−366,161→ 0 total→ Common Stock (366,161 underlying) - Conversion
Series A Conv Preferred Stock
2009-02-25−36,314→ 0 total→ Common Stock (36,314 underlying) - Conversion
Warrant
2009-02-25+5,157→ 5,157 totalFrom: 2006-07-19Exp: 2011-07-19→ Common Stock (5,157 underlying) - Conversion
Common Stock
2009-02-25+36,314→ 359,639 total - Disposition to Issuer
Common Stock
2009-02-25−359,639→ 0 total - Disposition to Issuer
Common Stock
2009-02-25−50,000→ 0 total(indirect: By Partnership) - Disposition to Issuer
Stock Option (right to buy)
2009-02-25−20,000→ 0 total→ Common Stock (20,000 underlying) - Disposition to Issuer
Stock Option (right to buy)
2009-02-25−15,000→ 0 total→ Common Stock (15,000 underlying) - Conversion
Warrant
2009-02-25−5,157→ 0 totalFrom: 2006-07-19Exp: 2011-07-19→ Series A Conv Preferred Stock (5,157 underlying) - Disposition to Issuer
Warrant
2009-02-25−5,157→ 0 total→ Common Stock (5,157 underlying) - Disposition to Issuer
Warrant
2009-02-25−13,810→ 0 total→ Common Stock (13,810 underlying) - Disposition to Issuer
Warrant
2009-02-25−20,000→ 0 total→ Common Stock (20,000 underlying)
Footnotes (7)
- [F1]Immediately prior to the consummation of the merger between the issuer and Replidyne, Inc., each share of Series A convertible preferred stoick was converted into approximately 1.005 shares of the issuer's common stock.
- [F2]Disposed of pursuant to a merger agreement among the issuer, Responder Merger Sub, Inc. and Replidyne, Inc. (now known as "Cardiovascular Systems, Inc."), pursuant to which each share of the issuer's common stock was converted into 0.647 shares of common stock of Replidyne, Inc.
- [F3]Shares held by Applecrest Partners LTD Partnership, of which Mr. Petrucci is the General Partner.
- [F4]Disposed of pursuant to a merger agreement among the issuer, Responder Merger Sub, Inc. and Replidyne, Inc. (now known as "Cardiovascular Systems, Inc."), pursuant to which each of the issuer's stock options was assumed by Replidyne, Inc. and became exercisable to purchase shares of Replidyne, Inc. common stock; each share covered by the issuer's options was converted into 0.647 shares of common stock of Replidyne, Inc., and the exercise price of each option was adjusted by dividing the pre-merger exercise price by 0.647 and rounding up to the nearest cent.
- [F5]Each share of Series A convertible preferred stock was convertible at any time, at the holder's election, into 1.005 shares of common stock and had no expiration date.
- [F6]Disposed of pursuant to a merger agreement among the issuer, Responder Merger Sub, Inc. and Replidyne, Inc. (now known as "Cardiovascular Systems, Inc."), pursuant to which each of the issuer's common stock warrants was assumed by Replidyne, Inc. and became exercisable to purchase shares of Replidyne, Inc. common stock; each share covered by the issuer's common stock warrants was converted into 0.647 shares of common stock of Replidyne, Inc., and the exercise price of each warrant was adjusted by dividing the pre-merger exercise price by 0.647 and rounding up to the nearest cent.
- [F7]Immediately prior to the consummation of the merger between the issuer and Replidyne, Inc., each Series A convertible preferred stock warrant was converted into a warrant to purchase the issuer's common stock; each Series A convertible preferred share covered by the warrants was converted into approximately 1.005 shares of the issuer's common stock and the exercise price of each warrant was adjusted by multiplying the number of Series A shares covered by the warrant by the warrant exercise price, and dividing by the total number of the issuer's common shares subject to the converted Series A warrant.
Documents
Issuer
CARDIOVASCULAR SYSTEMS INC
CIK 0001222929
Entity typeother
Related Parties
1- filerCIK 0001428155
Filing Metadata
- Form type
- 4
- Filed
- Feb 26, 7:00 PM ET
- Accepted
- Feb 27, 7:10 PM ET
- Size
- 36.0 KB